Skip to main content

Dopar Side Effects

Generic name: levodopa

Medically reviewed by Last updated on Apr 26, 2024.

Note: This document contains side effect information about levodopa. Some dosage forms listed on this page may not apply to the brand name Dopar.

Applies to levodopa: inhalation capsule.

Serious side effects of Dopar

Along with its needed effects, levodopa (the active ingredient contained in Dopar) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking levodopa:

More common

Less common

Other side effects of Dopar

Some side effects of levodopa may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

For Healthcare Professionals

Applies to levodopa: compounding powder, inhalation capsule, oral capsule, oral tablet.


The more commonly occurring adverse reactions have included cough, nausea, upper respiratory tract infection, and discolored sputum.[Ref]


Very common (10% or more): Cough (15%)

Common (1% to 10%): Discolored sputum, nasal discharge discoloration, oropharyngeal pain, upper respiratory tract infection, nasopharyngitis, bronchitis/pneumonia

In a crossover clinical study in subjects with mild or moderate asthma on a stable regimen of asthma medication (n=25), patients received orally inhaled drug 84 mg every 4 hours for a total of 3 doses and placebo. Cough was reported by 60% of subjects following drug administration compared with 0% following placebo. Ten subjects (40%) had temporary FEV1 reductions from baseline (between 15% and 59%), and 4 of these subjects also had a reduction in FEV1 following placebo. Subjects with a reduction in FEV1 remained asymptomatic and did not require rescue treatment.

Nervous system

Common (1% to 10%): Dyskinesia, headache

Frequency not reported: Falling asleep during activities of daily living, somnolence


Common (1% to 10%): Nausea, vomiting


Common (1% to 10%): Insomnia

Frequency not reported: Hallucinations

During clinical trials, hallucinations were reported in less than 2% of patients receiving orally inhaled levodopa.


Common (1% to 10%): Chest discomfort, orthostatic hypotension/blood pressure decreased



Common (1% to 10%): Laceration, skin abrasion


Common (1% to 10%): Increased blood bilirubin


Common (1% to 10%): Extremity pain


Common (1% to 10%): Fall


Common (1% to 10%): Decreased red blood cell count


Fever, altered consciousness, autonomic dysfunction and muscle rigidity are the hallmarks of the neuroleptic malignant syndrome. The neuroleptic malignant syndrome (NMS) is associated with a case fatality rate of about 20%. If withdrawal of dopaminergic therapy is suspected as the cause of NMS, dopaminergic therapy should be restarted. If a neuroleptic agent is suspected as the cause, the neuroleptic agent should be immediately discontinued. For patients with NMS suspected to be due to neuroleptic therapy, consideration should be given to dantrolene (or bromocriptine) administration. Intensive monitoring and supportive care are indicated for all patients with NMS.

Frequently asked questions


1. (2019) "Product Information. Inbrija (levodopa)." Acorda Therapeutics

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.